2. Academic Validation
  3. Targeting CD47 for cancer immunotherapy

Targeting CD47 for cancer immunotherapy

  • J Hematol Oncol. 2021 Oct 30;14(1):180. doi: 10.1186/s13045-021-01197-w.
Zhongxing Jiang  # 1,  Hao Sun  # 2,  Jifeng Yu 3 4,  Wenzhi Tian 5,  Yongping Song 6
Affiliations

Affiliations

  • 1 Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
  • 2 Department of Radiation Therapy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
  • 3 Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. yujifengzzu@163.com.
  • 4 Henan International Joint Laboratory of Nuclear Protein Gene Regulation, Henan University College of Medicine, Kaifeng, 475004, Henan, China. yujifengzzu@163.com.
  • 5 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd., Shanghai, 201203, China. wenzhi.tian@immuneonco.com.
  • 6 Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450008, Henan, China. Songyongping001@126.com.
  • # Contributed equally.
PMID: 34717705 DOI: 10.1186/s13045-021-01197-w
Abstract

Much progress has been made in targeting CD47 for Cancer Immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China. As of August 28, 2021, there are a total 23 related therapeutic agents with 46 clinical trials in the NCT registry platform. Among these trials, 29 are in ST, 14 in hematological malignancies and 3 in both solid tumor and hematological malignancy. The ST include gastric Cancer, head and neck squamous cell carcinoma and leiomyosarcoma, while the hematological malignancies include non-Hodgkin's lymphoma, acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and chronic myeloid leukemia. Majority of the CD47-related clinical trials are at the early phases, such as 31 at phase I, 14 at phase II and 1 at phase III in the USA and 9, 6, 1, in China, respectively. The targets and spectrums of mechanism of action include 26 with mono-specific and 20 with bi-specific targets in the USA and 13 with mono-specific and 3 with bi-specific targets in China. The new generation CD47 Antibodies have demonstrated promising results, and it is highly hopeful that some candidate agents will emerge and make into clinical application to meet the urgent needs of patients.

Keywords

Bi-specific antibody (BsAbs); CD47; Cancer immunotherapy; Clinical trials; Fusion proteins; Monoclonal antibody (mAbs); Signal regulatory protein α (SIRPα).

Figures
Products